Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederinvestor.lilly.com
Eli Lilly and Company News Releases
Get the latest updates from Eli Lilly and Company News Releases directly as they happen.
Follow now 265 followers
Latest posts
Last updated about 11 hours ago
Lilly's Verzenio® (abemaciclib) prolonged survival in HR+, HER2-, high-risk early breast cancer with two years of treatment
about 12 hours ago
Verzenio is the first contemporary therapy in over two decades to demonstrate...
Lilly confirms date and conference call for third-quarter 2025 financial results announcement
1 day ago
INDIANAPOLIS , Oct. 16, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE...
Lilly's oral GLP-1, orforglipron, demonstrated superior glycemic control in two successful Phase 3 trials, reconfirming its potential as a foundational treatment in type 2 diabetes
3 days ago
In ACHIEVE-2, orforglipron lowered A1C by up to 1.7% compared to 0.8%...
Lilly to present new clinical data for Verzenio (abemaciclib) and multiple novel pipeline programs at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting
5 days ago
Primary overall survival analysis from the Phase 3 monarchE study of Verzenio...
WHO Foundation and Lilly Collaborate to Support Global Dementia Action Plan
5 days ago
Berlin, October 13, 2025 -- The WHO Foundation and Lilly have announced...
Lilly's Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 antagonist to show four years of sustained, corticosteroid-free comprehensive patient outcomes in ulcerative colitis
11 days ago
Approximately 80% of Omvoh-treated patients in the LUCENT-3 study who achieved clinical...
Lilly opens newest Gateway Labs site in San Diego to boost local biotechnology ecosystem
21 days ago
New 82,514 square foot facility will accommodate up to 15 biotech companies...
Lilly's Kisunla (donanemab) receives marketing authorization by European Commission for the treatment of early symptomatic Alzheimer's disease
22 days ago
Approved for earliest symptomatic stages of disease, demonstrating significant slowing of cognitive...
U.S. FDA approves Inluriyo (imlunestrant) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer
22 days ago
An estimated 50% of patients with ER+, HER2 – metastatic breast cancer...
Lilly plans to build a new $6.5 billion facility to manufacture active pharmaceutical ingredients in Texas
24 days ago
The new Houston site, Lilly's eighth U.S. manufacturing facility announced since 2020...
Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, reduced A1C by an average of 2.2% in a Phase 3 trial of children and adolescents with type 2 diabetes
about 1 month ago
In SURPASS-PEDS, Mounjaro met the primary and all key secondary endpoints at...
Lilly's oral GLP-1, orforglipron, superior to oral semaglutide in head-to-head trial
about 1 month ago
For the primary endpoint, orforglipron lowered A1C by 2.2% vs. 1.4% with...